advertisement
The number of daily new COVID cases have dropped in India. The festival season, which includes Durga Puja and Diwali, where large groups of Indians gather, did not lead to a surge in cases. Epidemiological modellers had earlier predicted a third wave peaking during October and November.
Daily new cases have dropped from a peak of more than 400,000 cases per day in May 2021 to currently below 10,000 cases a day.
And while antibody tests might give us a clue as to why, we can’t get complacent about vaccination rates.
In India, “serosurveys” have been regularly conducted since the pandemic began. This is where blood is tested from large numbers of people to check for the presence of COVID antibodies.
Delhi reported 97 percent of people were positive for antibodies in October, including 80 percent of children. Some 95.3 percent of those immunised with the Indian version of the Astrazeneca vaccine Covishield had developed antibodies, as did 93 percent of those who received India’s own vaccine, Covaxin.
The state of Haryana’s serosurvey in October found antibodies in 76.3 percent of adults, upwards of 70 percent among children, and negligible difference between urban and rural populations.
Kerala had the lowest sero-prevalence of 44.4 percent in the fourth national serosurvey in July, but in October it had risen to 82.6 percent among the general population and 85.3 percent among residents of urban slums.
A third wave in India is an unlikely scenario with these high levels of antibodies, and vaccination levels continuing to rise.
The Centers for Disease Control in the US notes that both the fully vaccinated individuals and previously infected groups have a low risk of subsequent infection for at least six months.
“Patchwork vaccination” areas, where there are pockets of low coverage of vaccination among areas with high levels of coverage, run the risk of small outbreaks, but are unlikely to be large enough to be of any major epidemiological concern.
The WHO’s chief scientist said in late August that India seems to be “entering some stage of endemicity”. Endemic refers to the constant presence or usual prevalence of a disease in a population within a geographic area, where disease spread and rates are predictable.
Could a new variant, such as the Delta Plus subvariant first detected in India in April 2021 threaten the current relative stability? While it has been said it might be about 10–15 percent more transmissible than the Delta variant, the evidence from Europe suggests it has not yet been able to establish any dominance over Delta.
Of India’s 1.4 billion people, 26.9 percent are fully vaccinated and 54.9 percent have received at least one dose so far. But 35 million fewer women have been vaccinated compared to men and independent analyses show tribal and rural districts continue to lag.
There are two current targets: achieving 90 percent coverage of the first dose by the end of November and timely administration of the second dose. While the first is likely to be achieved, there are widespread reports of complacency regarding the second dose. A campaign is underway to encourage people to complete the schedule.
Districts with relatively low vaccine coverage require greater outreach efforts to reduce prevailing inequities. India’s immunisation programme has demonstrated its strengths in polio eradication and measles-rubella elimination campaigns. We need to borrow some of those techniques to ensure all Indians are protected against COVID.
(Rajib Dasgupta is the Chairperson, Centre of Social Medicine and Community Health at the Jawaharlal Nehru University)
(This is an opinion piece and the views expressed above are the author’s own. The Quint neither endorses nor is responsible for them. This article was originally published on The Conversation. Read the original article here.)
(At The Quint, we question everything. Play an active role in shaping our journalism by becoming a member today.)